Matching articles for "1328"

Screening Mammography for Women 40-49 Years Old

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
Conflicting recommendations on when to screen for breast cancer are problematic for healthcare providers. The recent recommendation by the US Preventive Services Task Force (USPSTF) against routine screening...
Conflicting recommendations on when to screen for breast cancer are problematic for healthcare providers. The recent recommendation by the US Preventive Services Task Force (USPSTF) against routine screening mammography for women 40-49 years old conflicts with recommendations made by other organizations such as the American Cancer Society and earlier recommendations made by the USPSTF in 2002.

Click here to view the free full article.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):97-8 | Show Full IntroductionHide Full Introduction

Rapid-Acting Insulin Analogues

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
Three rapid-acting insulin analogs are currently available: insulin lispro, insulin aspart and insulin glulisine. 1-3 All three are approved for use in both type 1 and type 2 diabetes, either by subcutaneous...
Three rapid-acting insulin analogs are currently available: insulin lispro, insulin aspart and insulin glulisine. 1-3 All three are approved for use in both type 1 and type 2 diabetes, either by subcutaneous injection, insulin pump or intravenous administration. All three cost more than regular insulin.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):98 | Show Full IntroductionHide Full Introduction

Bone Morphogenetic Protein (Infuse Bone Graft)

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
Harvesting of autogenous bone, most commonly from the iliac crest, for use as the interbody graft in spinal fusion procedures has been standard practice, but is associated with a high rate of morbidity,...
Harvesting of autogenous bone, most commonly from the iliac crest, for use as the interbody graft in spinal fusion procedures has been standard practice, but is associated with a high rate of morbidity, including graft site pain, infection, fracture, bleeding and damage to the femoral nerve. Use of recombinant human bone morphogenetic protein (rhBMP-2; Infuse Bone Graft - Medtronic) was first approved by the FDA in 2002 for single-level anterior lumbar spinal fusion in adults with degenerative disc disease who had not responded to at least 6 months of nonoperative treatment. Now it has also been approved for treatment of open tibial fractures and for use in oral and maxillofacial bone grafting procedures.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):99-100 | Show Full IntroductionHide Full Introduction

Drugs Past Their Expiration Date

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
Healthcare providers are often asked if patients can use drugs after their expiration date. Pharmaceutical companies, because of legal restrictions and liability concerns, will not sanction such use and might...
Healthcare providers are often asked if patients can use drugs after their expiration date. Pharmaceutical companies, because of legal restrictions and liability concerns, will not sanction such use and might not even comment on the safety or effectiveness of using their products beyond the date on the label. Since the last Medical Letter publication on this subject, more data have become available.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):100-1 | Show Full IntroductionHide Full Introduction

Ophthalmic Besifloxacin (Besivance)

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the...
The FDA has approved the fluoroquinolone besifloxacin 0.6% ophthalmic suspension (Besivance - Bausch & Lomb) for treatment of bacterial conjunctivitis caused by susceptible bacteria. According to the manufacturer, this product was developed specifically for ophthalmic use in a specialized vehicle designed to prolong contact time on the ocular surface. Besifloxacin is not available for systemic use.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):101-3 | Show Full IntroductionHide Full Introduction

Mercury in Fish

   
The Medical Letter on Drugs and Therapeutics • December 14, 2009;  (Issue 1327)
Recent news articles about mercury in fish may lead some patients to seek more information from their healthcare providers. For most Americans, seafood is the major source of exposure to mercury. The mercury in...
Recent news articles about mercury in fish may lead some patients to seek more information from their healthcare providers. For most Americans, seafood is the major source of exposure to mercury. The mercury in seafood is in the form of methylmercury, a potential neurotoxin formed by the organification of elemental mercury by marine microorganisms like plankton, which are then consumed by aquatic animals and concentrated up the food chain.
Med Lett Drugs Ther. 2009 Dec 14;51(1327):103-4 | Show Full IntroductionHide Full Introduction